RoslinCT Announces the Appointment of Dr. Derek Hei to its Scientific Advisory Board
17.8.2023 15:00:00 EEST | Business Wire | Press release
RoslinCT, a leading contract development and manufacturing organization (CDMO) for Advanced Cell and Gene therapies, announced the appointment of Derek Hei, Ph.D., to its Scientific Advisory Board (SAB). The SAB is comprised of cell and gene therapy pioneers with extensive experience, providing valuable insight into a range of topics for the development and manufacturing of advanced therapies.
Dr. Hei is Chief Technology Officer (CTO) at Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines. Dr. Hei’s deep expertise in the cell therapy space spans over two decades and has been leading manufacturing teams at biotechnology companies. He previously served as Chief of Manufacturing and Tech Ops at BlueRock Therapeutics, and SVP of Preclinical and Clinical Manufacturing, Cell and Gene Therapies, at Vertex Pharmaceuticals, where he was responsible for leading chemistry, manufacturing, and controls activities for multiple cell and gene therapy programs.
“Dr. Hei brings significant knowledge across many areas of cell and gene therapy development, including the production of cGMP-compliant cell therapies for clinical trials, and gene-edited induced pluripotent stem cell lines.” said Patrick Lucy, President and CEO of RoslinCT US, “He brings a unique and complementary perspective to our Scientific Advisory Board, and we are honored to welcome him.”
Peter Coleman, CEO of RoslinCT UK, commented: “The broad scientific expertise of our advisory board plays a crucial role in the development of advanced therapies by providing expert guidance, ensuring scientific rigor, and promoting safety and efficacy to accelerate innovation and improve patient outcomes. This is key to ensuring our continued growth. I am delighted to welcome Dr. Hei to our group.”
Dr. Hei joins the five board members previously appointed: Kenneth LeClair, Ph.D., Chair of the Board, Michael Chambers, Co-founder of Aldevron, Margit Jeschke, Ph.D., Independent Consultant, Michael Kalos, Ph.D., Founder and Managing Director at Next Pillar Consulting, and Michael Mendicino, Ph.D., Founder, President and Chief Consultant at Hybrid Concepts International.
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and supporting the development and future commercialization of cell therapies based on a broad range of cell types with an advanced program utilizing CRISPR-edited stem cell-based therapy.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide.
Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230817175472/en/
Contact information
Media Contact Information:
Carrie Zhang
Senior Director of Marketing
RoslinCT
E-mail: carrie.zhang@roslinct.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme Raises SEK 75 Million to Advance Its Commercial Biomanufacturing Strategy23.9.2026 15:07:00 EEST | Press release
Enginzyme AB has closed a new equity round raising SEK 75 million. The round marks a key milestone in the company's shift from R&D to a commercially driven strategy. "With our growth strategy established, closing this new investment round was a priority for enginzyme," said Aymeric de Gantes, enginzyme's CEO. "We are also very excited to welcome new shareholders with complementary expertise, who will all contribute to our mission to deliver biomanufacturing solutions for the personal care, food, and pharmaceutical industries. Our technology enables lower cost in use for higher-quality ingredients, obtained through more sustainable manufacturing processes." Lotus One Investment Pte. Ltd. and Valquest Partners Europe are joining the company as new shareholders and members of the Board of Directors. Sofinnova Partners, Stiftelsen Industrifonden, Navigare Ventures AB and Almi Invest GreenTech were key participants, combined with several other new and existing shareholders. On Thursday, Sep
SLB Awarded Major Contract by OQEP for Integrated Facility Expansion in Oman23.9.2026 15:04:00 EEST | Press release
SLB (NYSE: SLB) has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922635677/en/ SLB has been awarded a contract by OQ Exploration & Production (OQEP) to deliver the Bisat-B Expansion Production Facility in Oman. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. Under the contract, SLB will provide design, engineering, procurement, construction and commissioning services for the facility, along with four years of operations and maintenance support. The expansion will increase the facility’s gross fluids handling capacity to 548,000 barrels per day. The project is scheduled for completion within 19 months. The award marks the next phase of development for the Bisa
Datavault AI Announces Rights Offering to Shareholders23.9.2026 15:03:00 EEST | Press release
Datavault AI Inc. (Nasdaq: DVLT) (“Datavault AI” or the “Company”), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing and tokenization technologies, today announced that its board of directors (the “Board”) has approved a rights offering to holders of its common stock (“Common Stock”) and certain other Datavault AI securities. Moody Capital Solutions, Inc. (“Moody Capital”) will act as dealer manager for the rights offering. The Rights Offering to include investors in a process usually reserved exclusively for banks Under the rights offering, the Company will distribute, at no charge, transferable subscription rights to holders of record of Common Stock and certain other Company securities with a contractual right to participate in the distribution. The Company has set a record date of October 9, 2026 for such offering (the “Record Date”). Such holders will receive one subscription right for a Common Unit for each share of Common Stock owned
Copeland Completes Acquisition of Dickson, Advancing Cold Chain Intelligence for Healthcare and Life Sciences23.9.2026 15:00:00 EEST | Press release
Copeland, a global leader in compression technologies and controls solutions, today announced it has completed the acquisition of Dickson, a Chicago-based provider of environmental monitoring and compliance technology solutions for highly regulated life sciences and healthcare environments. Increasing regulatory demands across the pharmaceutical and life sciences cold chain require continuous visibility from production through final delivery. Together, Dickson’s cloud-native monitoring platform and Copeland’s controls, monitoring and enterprise software solutions will enable a more connected, intelligent and compliant cold chain. “We are pleased to welcome our new colleagues from Dickson into Copeland,” said Ross B. Shuster, CEO of Copeland. “The acquisition of Dickson further strengthens our ability to serve customers across every stage of the healthcare and life sciences cold chain, from pharmaceutical manufacturing through distribution and patient care.” Enabling a Smarter, More Con
Sitetracker and 5x5 Break the Price Barrier for Portfolio-Scale Digital Twins and Asset Intelligence23.9.2026 13:11:00 EEST | Press release
Sitetracker and 5x5 Technologies today introduced a data-to-twin workflow that gives wireless infrastructure owners a practical, affordable path to digitizing an entire tower portfolio. The Sitetracker platform now integrates 5x5 Synthetic Twin technology, providing scalable asset intelligence at a price up to 85% less than traditional site modeling methods. Synthetic Twins leverage Sitetracker’s leading tower portfolio and operational data to create interactive 3D models of towers, rooftops and ground compounds providing tower operators with a baseline of their portfolio that can be progressively enriched as the site conditions evolve. This data when combined with Scout, Sitetracker’s Agentic AI platform, opens the opportunity for digitized workflows and unparalleled understanding of the asset portfolio. Why it matters AI-driven data demand, more spectrum deployments, and denser infrastructure are raising the bar for tower operations. Towercos need precise knowledge of each site: what
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom